free web stats

Your Drug Injury Case Will Benefit From Our Years of Experience


Experienced drug injury lawyer

Attorney Tom Lamb

We have been representing patients and their family in drug injury lawsuits for the past 17 years and this is our main practice area.

Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.

Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.

Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.

We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.

If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.

We encourage you to submit a Drug Injury Case Review — it is free, confidential, and there is no obligation.  Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case.  Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.

We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.

While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.

It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.

In a rush? You can use our Quick Contact Form to tell us the basic information about your case.


Legal & Medical News: Featured Article

Health Canada Increases Warnings About Aranesp Skin Adverse Reactions

On May 5, 2017 the Canadian drug regulatory agency issued this Dear Healthcare Professional Letter: “ARANESP – Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis”.

From this recent Health Canada Aranesp alert we get this updated drug safety information:

  • In some patients, ARANESP has been associated with severe skin reactions, including life-threatening reactions called Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). SJS/TEN are serious life-threatening conditions that often begin with flu-like symptoms including fever, tiredness, muscle and joint pain which are followed by a widespread rash with reddening and blistering of the skin and moist lining of the mouth, eyes, nose, throat, or genital area. This often leads to peeling and shedding of the affected skin which looks like a severe burn. Patients should discuss any skin reaction with their doctor, and seek immediate medical attention if they experience any of the SJS/TEN symptoms.

  • As of October 31, 2016, cumulative exposure to ARANESP was estimated to be over 6 million patient-years in the post-marketing setting. The potential risk of SJS/TEN with ARANESP use was evaluated using the global safety databases. As of April 5, 2017, 11 cases of SJS and 4 cases of TEN have been reported internationally in patients treated with ARANESP. To date no Canadian cases of SJS/TEN related to ARANESP treatment have been identified.

This so-called “Dear Doctor” letter about Aranesp also informed that Health Canada is currently working with the manufacturer, Amgen Canada Inc., to include this safety information in the Canadian Product Monograph for Aranesp.

Aranesp (darbepoetin alfa) products for subcutaneous and intravenous use are approved by the FDA for two indications: (1) anemia due to chronic kidney disease; and, (2) anemia due to chemotherapy in patients with cancer.

We will be watching to see whether the FDA takes any similar regulatory action regarding the possible Aranesp side effects of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

[Read this article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
(800) 426-9535
Disclaimer and Copyright